Cite
HARVARD Citation
de Tute, R. et al. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of clinical oncology. 40 (25), pp. 2889-2900. [Online].